| Trial Title | Who can participate? | Where is the trial open? | What question is the trial asking? | Trial locations | Full trial information |
|---|---|---|---|---|---|
DP-IMRT Pancreas Trial:Phase I/II study of dose-escalated hypofractionated Dose-Painted Intensity Modulated Radiotherapy — A clinical trial testing whether higher, precisely targeted doses of radiotherapy can improve tumour control in pancreatic cancer without increasing side effects. Designed by Dr. Gerard McVey and Dr. Maeve Keys at SLRON, sponsored by Cancer Trials Ireland, and funded by the Pat Smullen Foundation. |
Adults with resectable or borderline resectable pancreatic adenocarcinoma who are fit to receive chemotherapy and radiotherapy, and have no evidence of cancer spread outside the pancreas (confirmed by CT/MRI/PET scans). Eligibility is confirmed through screening by the medical team. |
The trial is open in:
The trial will open in:
|
The study aims to find out whether dose-painted intensity modulated radiotherapy (DP-IMRT) — which allows higher, more focused radiation to the tumour while protecting healthy organs — can safely improve tumour control and surgical outcomes in pancreatic cancer. |
Globally: Irish-led investigator-initiated trial Ireland: 1 site open, 2 opening soon |
